On May 7, 2024 GC Genome Corporation, a leading diagnostics company, reported that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, May 31–June 4 (Press release, GC Genome, MAY 7, 2024, View Source [SID1234642814]). This research was conducted through a collaborative effort with Genece Health Inc., a strategic partner based in San Diego.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:

Title: Non-invasive colorectal cancer detection using multimodal deep learning ensemble classifier.

Date and Time: Saturday, June 1, 2024 9:00 AM – 12:00 PM CDT
Format: Poster Presentation
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Poster Board Number: 211
Abstract Number: 3066